Protalix BioTherapeutics, Inc. (AMEX:PLX) has scheduled a conference call for 29th October 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.protalix.com
Earnings Expectation
Protalix BioTherapeutics, Inc. biopharmaceutical firm, is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.08 per share from revenue of $ 13.56 million. Looking ahead, the full year loss are expected at $ 0.19 per share on the revenues of $ 61.27 million.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis.
